Trends in innovation for downstream process intensification, product yield, single use closed systems, and gentle ATMP bioprocessing: a KOL panel discussing 2024 insights in gene therapy manufacturing

Rachel Legmann, Senior Director of Technology, Gene Therapy, Repligen, and Andrew D Tustian, Senior Director of Viral Vector Process Development Group, Regeneron, discuss downstream AAV processes while exploring the trends in outsourcing versus in-house manufacturing and evolving supply chain solutions.

Please enter your email to access content Read now